Koers Zynex Inc. Other OTC
Aandelen
US98986M1036
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 227 mln. 208 mln. | Omzet 2025 * | 281 mln. 257 mln. | Marktkapitalisatie | 318 mln. 291 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 16 mln. 14,67 mln. | Nettowinst (verlies) 2025 * | 29 mln. 26,6 mln. | EV/omzet 2024 * | 1,4 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,13 x |
K/w-verhouding 2024 * |
20,3
x | K/w-verhouding 2025 * |
11,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 37,18% |
Recentste transcriptie over Zynex Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Sandgaard
CEO | Chief Executive Officer | 65 | 01-01-96 |
Daniel Moorhead
DFI | Director of Finance/CFO | 51 | 05-06-17 |
Anna Lucsok
COO | Chief Operating Officer | 38 | 01-02-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Barry Michaels
BRD | Director/Board Member | 74 | 10-01-18 |
Thomas Sandgaard
CEO | Chief Executive Officer | 65 | 01-01-96 |
Michael Cress
BRD | Director/Board Member | 66 | 10-01-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,64% | 212 mld. | |
+8,99% | 187 mld. | |
+29,83% | 155 mld. | |
+35,17% | 115 mld. | |
+2,55% | 65,5 mld. | |
+15,06% | 52,87 mld. | |
-6,47% | 45,25 mld. | |
-2,14% | 39,7 mld. | |
+6,88% | 37,72 mld. |